Picture of Dynavox AB logo

DYVOX — Dynavox AB News Story

0.000.00%
se flag iconLast trade - 00:00
TechnologySpeculativeMid CapFalling Star

Sweden's Dynavox Q2 revenue misses estimates on US market issues

Sweden's Dynavox Q2 revenue misses estimates on US market issues


Overview

  • Sweden assistive communication firm's Q2 revenue grew 11% but missed analyst expectations

  • Q2 operating profit more than doubled, with gross margin rising to 70%

  • Company completed acquisition of SR Labs Healthcare in Italy during the quarter


Outlook

  • Dynavox maintains long-term targets of 20% avg annual revenue growth (currency adjusted) and EBIT margin above 15%

  • Company says underlying market demand remains strong, but macroeconomic and geopolitical volatility persists

  • Dynavox expects to mitigate rising component costs through increased reimbursement levels and other measures


Result Drivers

  • BROAD-BASED DEMAND - Co said revenue growth was broad-based across geographies and product groups, reflecting continued demand for assistive communication solutions

  • OPERATING PLATFORM - Co attributed higher operating profit to benefits from a more streamlined and digitized operating platform, with non-recurring costs largely behind

  • NORTH AMERICA ORDER TIMING - Co said North America revenue benefited partly from delayed Q1 orders, though this was offset by more drawn-out prescription processes


Company press release: ID:nWkr5VFgsj


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

SEK 670 mln

SEK 680.78 mln (4 Analysts)

Q2 Gross Margin

70.00%

Q2 Operating Margin

15.70%

Q2 Operating Profit

SEK 105 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the integrated hardware & software peer group is "buy"

  • Wall Street's median 12-month price target for Dynavox Group AB is SEK111.00, about 70.1% above its July 21 closing price of SEK65.25

  • The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 25 three months ago


Reuters Recommended Reads

  • July 21 - Sweden's Asker Healthcare Q2 profit jumps on increased scale

  • July 22 - Sweden's Hansa Biopharma Q2 revenue dips

  • July 20 - Sweden's Devyser Diagnostics Q2 sales fall on distributor inventory adjustment


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Dynavox AB

See all news